RedMedEd

RedMedEd

Overview

At RedMedEd, increasing clinician competence and improving patient care is the name of the game.

With a track record of excellence in CME and a wide range of innovative gamification and interactive learning designs, the RedMedEd team delivers initiatives that are fresh, rigorous, engaging, and memorable.

When CME is done well, clinicians learn and patients win.


A Clinical Guide to Diagnosing and Treating Lyme Disease and Other Tick-Borne Illnesses

Overview Establishing a Lyme disease diagnosis remains a considerable challenge, as many symptoms are nonspecific and there are currently no definitive diagnostic tests available. This represents a significant clinical problem, as the number of Lyme disease cases in the U.S. is steadily increasing. This activity presents and discusses recent advances in the management of Lyme disease and other ...
Jointly provided by Postgraduate Institute for Medicine and RedMedEd, in collaboration with the State of Delaware and Global Lyme Alliance.

Ace the Case: A 17-Year-Old African American Patient With Systemic Lupus Erythematosus

This educational activity utilizes a case study to discuss treatment of 17-year-old Kayla, who was initially diagnosed at 11 and has recently been experiencing worsening headaches.
Postgraduate Institute for Medicine

Ace the Case: A 32-Year-Old African American Woman With Cutaneous Manifestations of Lupus

This educational activity utilizes a case study to discuss the diagnosis and treatment of a 32-year-old woman who seeks medical treatment after developing skin lesions.
Postgraduate Institute for Medicine

Ace the Case: A 37-Year-Old African American Woman With Lupus Nephritis

This educational activity utilizes a case study to discuss the management of a 37-year-old woman whose worsening systemic lupus erythematosus (SLE) indicates lupus nephritis.
Postgraduate Institute for Medicine

Ace the Case: A 42-Year-Old Woman With Anemia and Elevated Serum Total Protein

This educational activity will utilize a case study to discuss minimal residual disease measurement and treatment options for newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT).
Penn State College of Medicine, Multiple Myeloma Research Foundation, RedMedEd

Ace the Case: A 59-Year-Old Man With Multiple Myeloma Relapsing While on Lenalidomide Maintenance

Assessing treatment options for a relapsed multiple myeloma patient.
Penn State College of Medicine, Multiple Myeloma Research Foundation, RedMedEd

Ace the Case: A 62-Year-Old Man With Monoclonal Protein Detected on Routine Blood Work

This educational activity will utilize a case study to discuss the diagnostic and management options for a patient with smoldering multiple myeloma.
Penn State College of Medicine, Multiple Myeloma Research Foundation, RedMedEd

Ace the Case: A 62-Year-Old Woman With 45-Year History of Systemic Lupus Erythematosus

This educational activity utilizes a case study to discuss the ongoing monitoring and treatment of a 62-year-old woman with a 45-year history of systemic lupus erythematosus (SLE).
Postgraduate Institute for Medicine

Ace the Case: A 68-Year-Old Woman With Progressive Back Pain, Anemia, and Proteinuria

This educational activity will utilize a case study to discuss high-risk multiple myeloma and available treatment options.
Penn State College of Medicine, Multiple Myeloma Research Foundation, RedMedEd

Ace the Case: A 79-Year-Old Man With Anemia and High IgA Level

This educational activity utilizes a case study to discuss treatment options for transplant-ineligible multiple myeloma (MM) patients.
Penn State College of Medicine, Multiple Myeloma Research Foundation, RedMedEd

CLL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of novel targeted biologic agents in CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection (including drug combinations and sequencing ther...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Current Obstacles in Myeloma Management: Debating the Evidence

ACTIVITY DESCRIPTION The clinical multiple myeloma arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The approval of several new agents has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients....
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Immunotherapy for Multiple Myeloma: From Antibodies to CAR T–Cell Therapy

Multiple myeloma remains incurable, but the number and type of treatments continue to expand rapidly. A development that holds particular promise for patients with relapsed/refractory myeloma is the emergence of immunotherapy options such as antibody-based therapies, bispecific T-cell engagers, and chimeric antigen receptor T–cell therapy. Successful implementation of myeloma immunotherapy int...
Purdue University; Multiple Myeloma Research Foundation; RedMedEd

Managing Severe Asthma in the Era of Biologics: Early-Onset Asthma

In recent years, better understanding of asthma pathophysiology has led to the development of targeted biologics that have improved outcomes for some patients with severe asthma, and the Global Initiative for Asthma (GINA) guidelines now include biologics as a part of its stepwise treatment guidelines for personalized therapy. However, physicians continue to face challenges in determining when t...
University of Cincinnati and RedMedEd

Managing Severe Asthma in the Era of Biologics: Severe Persistent Eosinophilic Asthma

Although only a minority of asthma patients present with severe disease, these patients represent the greatest area of unmet clinical need in asthma care. A better understanding of asthma pathophysiology has resulted in the development of new targeted biologics in recent years, and this has improved outcomes for some patients with severe asthma and prompted the Global Initiative for Asthma (GINA...
University of Cincinnati and RedMedEd

MCL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Metastatic Hormone-Sensitive Prostate Cancer: Benefits and Risks of Current and Emerging Treatment Options

Prostate cancer is the most common cancer in men in the U.S.; in 2018, more than 3 million men were living with the disease. For men in whom prostate cancer is local or regional, 5-year survival approaches 100%. For those with metastatic hormone-sensitive prostate cancer (mHSPC), however, the 5-year survival rate is only 30%. Androgen deprivation therapy (ADT) has long been a treatment mainstay ...
Jointly provided by the University of Cincinnati and RedMedEd

Optimizing Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL and CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, ...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Oral Therapy for Outpatient Management of Multiple Myeloma: Options for the COVID-19 Era

Oncology health care providers (HCPs) who manage patients with multiple myeloma (MM) face new challenges during the COVID-19 pandemic—in particular, the need to balance the risk of delaying or altering MM therapy against the risk of disease progression in a patient population that is practicing social distancing and is at high risk of complications (or worse) from COVID-19. Successfully confro...
Jointly provided by Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation.

Relapsed/Refractory Multiple Myeloma: What’s Next for Patients?

Though treatable, multiple myeloma (MM) remains incurable. Patients inevitably experience relapse or develop resistance to initial multidrug combinations in spite of high complete response (CR) rates. The growing number of novel agents holds increasing promise of benefit for patients who relapse and/or become refractory to therapy, but improving the prognosis for these patients requires clinicia...
Purdue University College of Pharmacy

RME Hot Seat: Prognosis, Treatment Choice, and Risk Management for CLL and MCL

With the emergence of new targeted therapies and new prognostic indicators and goals of treatment, the clinical management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)—for patients in the frontline and relapsed/refractory settings—has evolved significantly. In this Q&A-based activity, our experts provide practical, evidence-based answers to questions relating to se...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Scale, Bail, or Fail – The B-Cell Lymphoma Edition

Over the last several decades, advances in non-Hodgkin B-cell lymphoma management—including non–chemotherapy-based targeted therapies and new cytogenetic and molecular prognostic testing—have significantly improved patient survival. For clinicians who provide care to patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), keeping pace with these advances and incorp...
Jointly provided by the Nurse Practitioner Healthcare Foundation (NPHF), RedMedEd, and Horizon CME.

Treatment Options for Multiple Myeloma Patients Who Have Relapsed From or Are Refractory to Multiple Therapies

ACTIVITY DESCRIPTION Multiple myeloma (MM) patients inevitably experience relapse or develop resistance to initial multidrug combinations in spite of high complete response rates, but a growing number of these patients are benefiting from the availability of several novel agents. Patients who have not responded satisfactorily to the three main classes of drugs currently used to treat myeloma (p...
Multiple Myeloma Research Foundation, RedMedEd, and Purdue University

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.